Quantisnow Logo
Dashboard

SEC Form DEFA14A filed by Biohaven Ltd.

$BHVN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BHVN alert in real time by email
DEFA14A 1 a2025bhvndefa14aproxynotice.htm DEFA14A Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ý
Filed by a Party other than the Registrant o
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
ý
Definitive Additional Materials
o
Soliciting Material Pursuant to §240.14a-12
BIOHAVEN LTD.
(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
ý
No fee required.
o
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:
(2)
Aggregate number of securities to which transaction applies:
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0‑11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)
Proposed maximum aggregate value of transaction:
(5)
Total fee paid:
o
Fee paid previously with preliminary materials.
o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:
(2)
Form, Schedule or Registration Statement No.:
(3)
Filing Party:
(4)Date Filed:



biohavenltd_naxp26374xp263.jpg


biohavenltd_naxp26374xp263a.jpg
Get the next $BHVN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BHVN

DatePrice TargetRatingAnalyst
2/11/2025$65.00Buy
Deutsche Bank
9/16/2024$57.00Buy
Jefferies
9/4/2024$55.00Outperform
Bernstein
7/24/2024$58.00Overweight
Morgan Stanley
2/16/2024$62.00Outperform
RBC Capital Mkts
2/6/2024$59.00Buy
UBS
12/22/2023$50.00Buy
H.C. Wainwright
12/8/2023$58.00Outperform
Robert W. Baird
More analyst ratings

$BHVN
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

    Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn-targeting competition.Up to 84% reduction of total IgG was observed with a median reduction of 80% after subcutaneous weekly 1000 mg dosing in the ongoing Phase 1 study.Subcutaneous BHV-1300 achieved progressive reductions in IgG levels within hours of each weekly dose administration, and pharmacodynamic effects were sustained compared to baseline over the four-week period.Dose escalation with BHV-1300 continues in the study and plans to explore deeper reductions to characterize the potential r

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

    Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025.Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million.Reported positive degrader data with multiple doses of BHV-1300 achieving up to 84% reduction of total IgG, with a median reduction of 80%, after subcutaneous weekly 1000 mg dosing in the ongoing Phase 1 study.Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differ

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

    Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment.Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the primary and secondary outcome measures at the 3-year endpoint in a real-world evidence (RWE) study.Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025.NEW HAVEN, Conn., Feb. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven or the Company), today announced that the US Food and Drug Administration (FDA) ha

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BHVN
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BHVN
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BHVN
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BHVN
 SEC Filings

See more

$BHVN
 Leadership Updates

Live Leadership Updates

See more

  • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

    Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy

    NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.   Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. K

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BHVN
 Financials

Live finance-specific insights

See more

  • Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

    Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

    Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

    Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BHVN
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more